STGen Bio Signs Biopharmaceutical Manufacturing Contract Worth 9.8 Billion KRW

16.7% of Sales Volume
Accelerating Entry into the CMO Market with Superior Quality

Exterior view of STGen Bio. Photo by STGen Bio

STGen Bio announced on June 13 through a public disclosure that it has signed a contract for the contract manufacturing of biopharmaceuticals. The total contract amount is 9.8 billion KRW, which corresponds to 16.78% of its recent sales of 58.8 billion KRW.

The contract period is three years, from June 2025 to May 2028. The client company and product name are not disclosed due to confidentiality clauses.

As a biopharmaceutical CMO specialist of the Dong-A Socio Group, STGen Bio is actively securing orders. By providing a wide range of manufacturing services, including drug substances (DS), drug products (DP), and commercial-scale production, the company demonstrates its global competitiveness.

In particular, among domestic CMO companies, STGen Bio's strength lies in its unique capability to provide one-stop production from DS to PFS (pre-filled syringe) filling at a single site with cGMP (current Good Manufacturing Practice) certified manufacturing facilities.

Based on these advanced capabilities, the company passed inspections by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) simultaneously, and received GMP certification from regulatory authorities in eight countries, including the United Kingdom, Thailand, and Turkiye.

A representative from STGen Bio stated, "Based on our advanced DP and DS systems, we plan to secure strategic global partners and establish a service platform covering all areas of CMO. We will continue to achieve sustainable growth by securing differentiated competitiveness in new modalities, quality, and manufacturing sectors."

This content was produced with the assistance of AI translation services.